期刊
CANCER CELL
卷 23, 期 5, 页码 618-633出版社
CELL PRESS
DOI: 10.1016/j.ccr.2013.03.013
关键词
-
资金
- Ludwig Institute for Cancer Research
- Oxford NIHR Biomedical Research Centre
- Structural Genomics Consortium (SGC)
- Medical Research Council, UK
- Cancer Research UK [8466, 14414] Funding Source: researchfish
- Medical Research Council [G0800014] Funding Source: researchfish
- MRC [G0800014] Funding Source: UKRI
Nearly 90% of human melanomas contain inactivated wild-type p53, the underlying mechanisms for which are not fully understood. Here, we identify that cyclin B1/CDK1-phosphorylates iASPP, which leads to the inhibition of iASPP dimerization, promotion of iASPP monomer nuclear entry, and exposure of its p53 binding sites, leading to increased p53 inhibition. Nuclear iASPP is enriched in melanoma metastasis and associates with poor patient survival. Most wild-type p53-expressing melanoma cell lines coexpress high levels of phosphorylated nuclear iASPP, MDM2, and cyclin B1. Inhibition of MDM2 and iASPP phosphorylation with small molecules induced p53-dependent apoptosis and growth suppression. Concurrent p53 reactivation and BRAFV600E inhibition achieved additive suppression in vivo, presenting an alternative for melanoma therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据